Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-U
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EB-U is an oral rehydration salts (ORS) formulation developed and marketed by Anglo-French Drugs & Industries. It is designed to restore body fluids and essential electrolytes lost due to dehydration, particularly that caused by diarrhea, sweating, or illness. The formulation typically contains a balanced mixture of sodium chloride, potassium chloride, sodium citrate, and dextrose (glucose). This combination facilitates the co-transport of sodium and water across the intestinal epithelium via the sodium-glucose cotransporter 1 (SGLT1), thereby promoting rapid rehydration.
- Brand names
- EB-U
- Other names
- EB-U (ORAL REHYDRATION SALTS)Oral Rehydration Salts
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)
Beyond the preview
Go deeper on EB-U.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-U.